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Schizophrenia syndrome due to C9ORF72
mutation case report: a cautionary tale and
role of hybrid brain imaging!
A. M. Burhan1,2,3* , U. C. Anazodo1, N. M. Marlatt4, L. Palaniyappan5, M. Blair1,6 and E. Finger1,7

Abstract
Background: Frontal variant frontotemporal dementia is a common cause of presenile dementia. A hexanucleotide
expansion on chromosome 9 has recently been recognized as the most common genetic mutation cause of this
illness. This sub-type tends to present psychiatrically with psychosis being a common presenting symptom before
the onset of cognitive changes or brain atrophy. A few case series have been published describing the prominence
of early psychotic symptoms, and lack of clear brain atrophy on clinical brain imaging imposing a challenge in
reaching early accurate diagnosis. In this report, we present a case whereby the diagnosis of Schizophrenia
syndrome was made and the patient was treated for years with multiple interventions for that syndrome before
reaching the accurate diagnosis of Frontal variant frontotemporal dementia due to hexanucleotide expansion on
chromosome 9. This diagnosis was confirmed after genetic testing and findings on a hybrid Positron Emission
Tomography/Magnetic Resonance Imaging scanning.
Case summary: A 60-year-old female diagnosed with schizophrenia at age 50 after presenting with delusions and
hallucinations, which proved to be refractor to several lines of pharmacological and non-pharmacological
interventions including electroconvulsive therapy. Patient had a history of post-partum psychosis in her 20s. She
was referred to cognitive neurology due to progressive decline in function. While clinical structural brain imaging
data were not adequate to support an alternative neurological diagnosis, careful inquiry elicited a history of
psychotic illness followed by progressive decline in a sister. Genetic testing confirmed hexanucleotide expansion on
chromosome 9 mutation. The patient was offered a state-of-the-art FD-Glucose Positron Emission Tomography/
Magnetic Resonance Imaging scan available at our centre. While volumetric Magnetic Resonance Imaging scan did
not show volume loss in frontotemporal areas, the hybrid scan showed regionally specific deficit in FD-Glucose
Positron Emission Tomography affecting medial superior frontal, insula, inferior temporal, thalamus, and anterior
cingulate cortex consistent with behavioral variant frontotemporal dementia.
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Conclusions: This case highlights the importance of considering Frontal variant frontotemporal dementia due to
hexanucleotide expansion on chromosome 9 when facing relatively late-onset, refractory schizophrenia-like
syndrome. Careful history from all available sources to elicit family history of similar presentation is very important.
Genetic testing and functional brain imaging can aid in confirming the diagnosis and potentially streamlining the
management of these cases.
Keywords: Case report, bvFTD, Schizophrenia, PET/MRI, C9ORF72

Background
Frontotemporal dementia (FTD) represents a relatively
heterogeneous group of pathologies affecting frontal and
temporal lobes of the brain and results in related, but
distinguishable clinical presentations [1, 2]. A hexanucleotide expansion on chromosome 9 (C9ORF72) has
been identified as the most common genetic mutation of
behavioural variant FTD (bvFTD), amyotrophic lateral
sclerosis (ALS), and the combination of the two [3]. Patients with C9ORF72 mutation tend to have more frequent and severe psychiatric symptoms (especially
psychosis) at presentation, less brain atrophy on imaging
and slower disease progression [4], with psychiatric
symptoms preceding other features of dementia by several years [5, 6]. The lack of obvious atrophy on brain
imaging, in these cases, can deviate attention from the
possibility of FTD resulting in ongoing treatment as a
psychiatric disorder and ultimately difficulty for the
patient and care providers. Because of the presenile presentation, some patients are treated as having schizophrenia, with possible success early on, but eventually these
patients show progressive cognitive and behavioural decline. Advances in functional brain imaging have allowed
for the detection of synaptic dysfunction, prior to brain
volume loss (atrophy), thereby offering the opportunity
to inform accurate diagnosis prior to significant brain
atrophy. In this case report, we present a patient who
participated in a study of the utility of 18F-Flourodexoyglucose-Positron Emission Tomography (FDG-PET) for
patients with FTD and obtained a PET- Magnetic Resonance Imaging (MRI) scan. Written consent was obtained from the patient’s substitute decision maker to
publish deidentified details of the case. The consent is
filed in permanent medical records at the Saint Joseph’s
Health Care-London in London Ontario Canada.
This case is unique because the patient was diagnosed
in early 50s with a full-blown syndrome of schizophrenia, received extensive inpatient and outpatient
pharmacological and non-pharmacological interventions
including psychotherapies and ECT, continued to be refractory and continued to decline despite all efforts.
Most bvFTD due to C9ORF72 cases reported in the literature came from neurological clinics with psychosis
being common in the presentation but not to the extent
of a full-blown syndrome of schizophrenia and to the

level of extensive tertiary care level psychiatric management that this case received.

Case presentation
We describe a case of a 60-year-old white, right-handed
married female, mother of three grown up children, who
completed 13 years of formal education. The patient first
presented to psychiatry at age 50 with both visual and
auditory hallucinations, including command hallucinations to kill her family, which were very distressing to
her. Importantly, detailed history revealed the onset of
paranoid delusions in her 20s, following an episode of
post-partum psychotic depression. These included delusions that her neighbors, dentist and coworkers were
spying on her, had bugged her house, and at times flew
planes over her home to look into the windows. She was
able to raise a family and work as an administrative assistant in her 30s and 40s. She was diagnosed with
schizophrenia, paranoid type, at her first presentation to
psychiatry at age 50, with subsequent diagnosis of schizoaffective disorder due to episodes of depression, and
episodes of psychosis independent of mood. She has a
family history of schizophrenia in two of her siblings including a recent history of schizophrenia-like illness with
rapid cognitive and functional decline in her sister who
was placed in a nursing facility and subsequently passed
away with a diagnosis of “dementia” not otherwise
specified.
Since her diagnosis she required both inpatient and
outpatient psychiatric care and case management. She
received psychotherapeutic supportive care in addition
to pharmacological interventions, specifically atypical
antipsychotic medications including olanzapine (up to
40 mg daily) with clonazepam, and then clozapine (up to
400 mg daily) with improvement in the psychotic symptoms. At age 59 her illness became more resistant to
treatment with prominent catatonic features (limited activity level, low oral intake, staying in bed all day and
not being able to function in almost all areas). Clinical
computed tomography (CT)-Scan and 1.5 T MRI did not
show any focal abnormalities and no general or focal atrophy. At that time, electroconvulsive therapy (ECT)
was offered to help with the resistant psychosis and the
catatonic features given the efficacy of ECT in catatonic
psychosis [7]. With 15 sessions of bilateral lead

Burhan et al. BMC Psychiatry

(2021) 21:331

placement ECT treatment she became more impaired
with increased confusion, further impairment in functioning and memory, inappropriate binge eating and
newly emergent disinhibition. A consultation with cognitive neurology was requested to clarify diagnosis. No
focal or lateralizing neurological signs where identified.
Clinical CT-Scan and MRI were again read “within normal” by the cognitive neurologist (EF) but upon further
inquiry and because of the family history of the rapid decline and dementia in her sister, further work-up with
genetic testing was ordered to rule out genetic variants
of frontotemporal dementia. The latter came back positive for C9ORF72 repeat expansion. Recommendation
provided to stop ECT, discuss care implications with
substitute decision maker (husband) including access to
home-based dementia and assuring environmental
safety, providing access to adult day program for safe activation, and judicial symptomatic treatment with psychotropic medications under the supervision of a old age
psychiatrist specialized in the care of neuropsychiatric
aspects of dementia. Patient has been in follow-up at the
geriatric psychiatry adult day program twice a week and
under the care of a geriatric psychiatrist (AB) for over 2
years with slowly progressive decline but with no further
need for inpatient admission or ECT. Cognitive neurology (EF) continues to review every 6 months to monitor for any other emerging symptoms. Husband
continues to attend meetings and assure adherence to
management plans with support from outreach nurses
from the clinic.
PET/MR imaging methods

PET and MRI brain imaging were acquired simultaneously on an integrated PET/ 3 T MRI system (Siemens
Biograph mMR, Siemens Healthineers, Erlangen,
Germany) after six hours of fasting. The PET imaging
was acquired as a 60-min dynamic scan in listmode immediately following a single bolus intravenous injection
of 110.27 MBq of 18F-Flourodexoyglucose (FDG). The
pre-injection blood glucose was 4.9 mmol/L. Head
movement was minimized using an immobilizing head
mold (Alpha Cradle®, Smithers Medical Products). PET
image volumes acquired at 30 to 45 min were reconstructed to one image volume, 2.1 × 2.1 × 2.0 mm3 voxel
size using an ordered-subsets expectation maximization
algorithm (3 iterations, 21 subsets, Gaussian filter with a
full-width half maximum of 2 mm and 2.5 zoom factor)
with point-spread function model. An ultrashort echo
time (UTE) MRI sequence was acquired for MR-based
attenuation correction (MRAC) using default parameters; repetition time (TR)/echo time 1 (TE1)/echo time 2
(TE2) =11.94/0.07/2.26 ms, flip angle = 10 degrees, total
acquisition time (TA) = 1.19 s, 192 slices and 192 × 192
matrix size. The MRAC μ-map was generated using the
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RESOLUTE [8] approach by segmenting the UTE images to air, brain, cerebral spinal fluid (CSF) and soft tissue, and assigning linear attenuation coefficients to
tissue segments. The accuracy of RESOLUTE MRAC is
comparable to CT-based attenuation correction with an
average error of less than 2% across the brain [8]. The
diagnostic image quality of the non-attenuation corrected PET, attenuation corrected PET (PET-AC) and
MRAC μ-map were visually inspected by a board certified Nuclear Medicine Physician.
Anatomical MR imaging method

A T1-weighted anatomical MRI scan was performed
during dynamic PET imaging to further explore findings
from prior clinical anatomical scans. The T1-weighted
sequence consisted of 3D magnetization-prepared rapid
gradient echo (MPRAGE) with TR/TE = 2000/2.98 ms,
inversion time = 900 ms, flip angle = 9 degrees, 256 × 256
matrix, 176 slices (1 mm3 isotropic), and acceleration
factor of 2.
Image analysis

To quantify and characterize evidence of neurodegeneration, the patient’s T1-weighted and PET-FDG images
were compared voxel-by-voxel to a database of scans
from 10 healthy older adults (Mean age; 67 ± 6 years, 4
males/6 females, mean FDG dose; 202.73 ± 30.85 MBq,
mean blood glucose; 4.7 ± 0.6 mmol/L). The control
database was acquired as part of a separate prospective
study on the PET/MRI using the same imaging protocol
as the patient scan. Prior to single subject voxel-based
analysis, the patient and control T1-weighted images
were converted to gray matter probability maps using
voxel-based morphometric analysis methodology outlined in [9]. The PET images were smoothed with 10
mm Gaussian filter, corrected for partial volume effects
[10] and count normalized to individual cerebellar gray
matter mean, the most preserved area of the brain in
FTD patients. All images were spatially aligned to the
standard MNI space. A t-statistic map for the patient’s
T1-weighted and PET images were computed using the
modified t-test proposed by Crawford and Howell [11]
that allows inferences on an individual’s deviation from
the group norm. Positive findings were identified as voxels with t-values > 2 at p < 0.05, signifying areas of decreased gray matter volume or glucose uptake relative to
controls.
PET/MR imaging findings

The results from voxel-based single subject analysis
matched qualitative evaluation by a nuclear medicine
physician. No significant atrophy was observed on T1weighted images both qualitatively and quantitatively,
confirming prior clinical reports of normal brain
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morphology in some patients with bvFTD with C9orf72
[12] (see Fig. 1 - top section). Decreased FDG uptake
was visible in the frontal and temporal regions of the
brain (see Fig. 1 - top section). FDG-PET revealed hypometabolism in medial superior frontal, insula, inferior
temporal, thalamus, and anterior cingulate cortex (see
Fig. 1 - bottom section).

Discussion and conclusions
In this paper, we report a case of typical schizophrenia
syndrome for decades, which was eventually diagnosed as
bvFTD with C9ORF72 repeat expansion mutation. Clinical structural imaging did not support the diagnosis of
FTD, but further work-up triggered by ECT-related functional decline, led to interdisciplinary assessment, genetic
confirmation and FDG-PET imaging. Notably, FDG-PET
demonstrated a pattern of hypometabolism in frontotemporal areas, especially affecting the brain regions constituting the Salience Network as previously described in FTD
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[13], which is also reported to be highly relevant to the
clinical expression of psychosis [14].
This case report raises several important practice points.
First, it reinforces the prior reports that C9ORF72 variant
of bvFTD presents in a manner often indistinguishable
from primary psychotic disorders. Current consensus
guidelines to distinguish bvFTD from primary psychosis
recommend early interdisciplinary assessment (neurology
and psychiatry), neuropsychological assessment with
structured testing of social cognition, and standardized review of structural MRI to assess atrophy along with FDGPET study [12]. Genetic testing is recommended in all
cases of suspected bvFTD with a family history of FTD/
ALS. C9ORF72 testing is recommended even if there is no
family history, given its frequent appearance (~ 6%) in
sporadic FTD [15]. Secondly, while the prevalence of
C9ORF72 repeat expansion mutations is not known to be
higher than expected among patients with schizophrenia,
late onset cases (> 40 years of age) with family history of

Fig. 1 Top section - Axial and sagittal slices of the patient’s brain acquired on a PET/MRI; T1-weighted anatomical (left), FDG-PET (middle) and
FDG-PET overlaid onto T1-weighted (right). No significant brain atrophy was detected on volumetric measurement of T1-weighted images.
Decreased FDGuptake was visible in the frontal and temporal regions of the brain. Bottom section - FDG-PET t-map (t > 2, p < 0.05) overlaid to
the standard MNI T1-weighted image. Areas of hypometabolism (blue-green) were observed in medial superior frontal, insula, inferior temporal,
thalamus, and anterior cingulate cortex
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unknown degenerative illnesses or long-term psychiatric
institutionalization should carry a low threshold for
C9ORF72 evaluation. Third, we report an FDG-PET finding that shows striking hypometabolism in the Salience
Network, a large-scale brain network that also has a critical role in the pathophysiology of schizophrenia [16], in
addition to frontotemporal reduction characteristic of
other variants of FTD. Of interest, bilateral insula, anterior
cingulate cortex and thalamus constituting the Salience
Network are also the most likely regions of grey matter reduction in schizophrenia [17]. On this basis, we highlight
the need for further studies quantifying single-subject’s
deviation from the norm of FDG-PET profile of this network in age-matched healthy individuals when assessing
possible bvFTD in late-onset psychosis. Finally, cognitive
and functional deterioration with ECT in a case of lateonset psychosis should prompt an evaluation for neurodegenerative disorders, as we note in this case.
This is a single case study with the inherent limitation
in generalizing the results to other cases presenting with
similar diagnostic dilemma. Another limitation is related
to lack of detailed neurological and neuropsychological
work-up at baseline, which makes it difficult to identify
the role of subtle early cognitive/emotional processing
or neuroimaging markers in identifying cases of bvFTD
due to C9ORF72. On the other hand, this patient had a
very detailed and long highly specialized psychiatric
follow-up including the involvement of several psychiatrists, psychologists, nurses and other mental health
workers all of which considered the illness as a typical
schizophrenia illness initially, and later on as schizoaffective illness. We had access to a highly specialized cognitive neurology and neuroimaging centre that allowed us
to confirm beyond doubt the diagnosis, which might not
be available everywhere. On the other hand, we think
that highlighting the clinical markers of special concern
can trigger referral to specialized centres that has the
capability to provide detailed work-up and reduce burden on the patient, family and system of care.
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